| Primary |
| Diabetes Mellitus Non-insulin-dependent |
25.0% |
| Glucose Tolerance Impaired |
25.0% |
| Polycystic Ovaries |
25.0% |
| Type 1 Diabetes Mellitus |
25.0% |
|
| Diarrhoea |
20.0% |
| Headache |
20.0% |
| Pharmaceutical Product Complaint |
20.0% |
| Pruritus |
20.0% |
| Therapeutic Response Unexpected With Drug Substitution |
20.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
75.0% |
| Hypertension |
25.0% |
|
| Angioedema |
33.3% |
| Medication Error |
33.3% |
| Vision Blurred |
33.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.2% |
| Type 2 Diabetes Mellitus |
10.4% |
| Diabetes Mellitus |
7.5% |
| Hypertension |
6.8% |
| Depression |
3.3% |
| Gastrooesophageal Reflux Disease |
3.0% |
| Asthma |
2.7% |
| Blood Cholesterol Increased |
2.7% |
| Hypersensitivity |
2.7% |
| Pain |
2.7% |
| Rheumatoid Arthritis |
2.5% |
| Drug Use For Unknown Indication |
2.3% |
| Chronic Obstructive Pulmonary Disease |
2.2% |
| Insomnia |
2.0% |
| Headache |
1.8% |
| Hepatitis C |
1.8% |
| Anxiety |
1.7% |
| Diabetes Mellitus Non-insulin-dependent |
1.7% |
| Bipolar Disorder |
1.5% |
| Blood Cholesterol |
1.5% |
|
| Weight Decreased |
13.6% |
| Vomiting |
12.1% |
| Pulmonary Embolism |
10.6% |
| Nausea |
6.1% |
| Off Label Use |
6.1% |
| Pain |
6.1% |
| Respiratory Tract Congestion |
4.5% |
| Somnolence |
4.5% |
| Blood Glucose Abnormal |
3.0% |
| Blood Glucose Decreased |
3.0% |
| Blood Glucose Increased |
3.0% |
| Death |
3.0% |
| Drug Ineffective |
3.0% |
| Injection Site Haemorrhage |
3.0% |
| Local Swelling |
3.0% |
| Nasopharyngitis |
3.0% |
| Palpitations |
3.0% |
| Pneumonia |
3.0% |
| Presyncope |
3.0% |
| Product Quality Issue |
3.0% |
|
